<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In the last years progress has been made regarding the involvement of the thalamus during the course of the currently known polyglutamine diseases </plain></SENT>
<SENT sid="1" pm="."><plain>Although recent studies have shown that the thalamus consistently undergoes <z:hpo ids='HP_0002180'>neurodegeneration</z:hpo> in <z:e sem="disease" ids="C0020179" disease_type="Disease or Syndrome" abbrv="HD">Huntington's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) and spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> type 2 (SCA2) it is still unclear whether it is also a consistent target of the <z:mpath ids='MPATH_596'>pathological process</z:mpath> of spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> type 3 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Accordingly we studied the thalamic pathoanatomy and distribution pattern of ataxin-3 immunopositive <z:mp ids='MP_0004191'>neuronal intranuclear inclusions</z:mp> (NI) in nine clinically diagnosed and genetically confirmed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e> patients and carried out a detailed statistical analysis of our findings </plain></SENT>
<SENT sid="3" pm="."><plain>During our pathoanatomical study we disclosed (i) a consistent degeneration of the ventral anterior, ventral lateral and reticular thalamic nuclei; (ii) a degeneration of the ventral posterior lateral nucleus and inferior and lateral subnuclei of the pulvinar in the majority of these <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e> patients; and (iii) a degeneration of the ventral posterior medial and lateral posterior thalamic nuclei, the lateral geniculate body and some of the limbic thalamic nuclei in some of them </plain></SENT>
<SENT sid="4" pm="."><plain>Upon immunocytochemical analysis we detected NI in <z:hpo ids='HP_0000001'>all</z:hpo> of the thalamic nuclei of <z:hpo ids='HP_0000001'>all</z:hpo> of our <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e> patients </plain></SENT>
<SENT sid="5" pm="."><plain>According to our statistical analysis (i) thalamic <z:hpo ids='HP_0002180'>neurodegeneration</z:hpo> and the occurrence of ataxin-3 immunopositive thalamic NI was not associated with the individual length of the CAG-repeats in the mutated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e> allele, the patients age at disease <z:hpo ids='HP_0003674'>onset</z:hpo> and the duration of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e> and (ii) thalamic <z:hpo ids='HP_0002180'>neurodegeneration</z:hpo> was not correlated with the occurrence of ataxin-3 immunopositive thalamic NI </plain></SENT>
<SENT sid="6" pm="."><plain>This lack of correlation may suggest that ataxin-3 immunopositive NI are not immediately decisive for the fate of affected nerve cells but rather represent unspecific and pathognomonic morphological markers of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e> </plain></SENT>
</text></document>